Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 32

1.

Preclinical imaging and treatment of cancer - The use of animal models beyond rodents.

Axiak-Bechtel SM, Maitz CA, Selting KA, Bryan JN.

Q J Nucl Med Mol Imaging. 2015 Jul 22. [Epub ahead of print]

PMID:
26200223
2.

Fetal Microchimerism in Cancer Protection and Promotion: Current Understanding in Dogs and the Implications for Human Health.

Bryan JN.

AAPS J. 2015 May;17(3):506-12. doi: 10.1208/s12248-015-9731-y. Epub 2015 Feb 19. Review.

PMID:
25693490
3.

6-Thioguanine and zebularine down-regulate DNMT1 and globally demethylate canine malignant lymphoid cells.

Flesner BK, Kumar SR, Bryan JN.

BMC Vet Res. 2014 Dec 6;10:290. doi: 10.1186/s12917-014-0290-8.

4.

Gum arabic-coated radioactive gold nanoparticles cause no short-term local or systemic toxicity in the clinically relevant canine model of prostate cancer.

Axiak-Bechtel SM, Upendran A, Lattimer JC, Kelsey J, Cutler CS, Selting KA, Bryan JN, Henry CJ, Boote E, Tate DJ, Bryan ME, Katti KV, Kannan R.

Int J Nanomedicine. 2014 Oct 28;9:5001-11. doi: 10.2147/IJN.S67333. eCollection 2014.

5.

Bacterial quorum sensing molecule N-3-oxo-dodecanoyl-L-homoserine lactone causes direct cytotoxicity and reduced cell motility in human pancreatic carcinoma cells.

Kumar AS, Bryan JN, Kumar SR.

PLoS One. 2014 Sep 4;9(9):e106480. doi: 10.1371/journal.pone.0106480. eCollection 2014.

6.

Zebularine significantly sensitises MEC1 cells to external irradiation and radiopharmaceutical therapy when administered sequentially in vitro.

Bryan JN, Kumar SR, Jia F, Balkin ER, Lewis MR.

Cell Biol Int. 2014 Feb;38(2):187-97. doi: 10.1002/cbin.10215. Epub 2013 Dec 9.

7.

The health effects of fetal microchimerism can be modeled in companion dogs.

Kumar SR, Hansen SA, Axiak-Bechtel SM, Bryan JN.

Chimerism. 2013 Oct-Dec;4(4):139-41. doi: 10.4161/chim.26509. Epub 2013 Sep 30.

8.

Nanoparticulate paclitaxel demonstrates antitumor activity in PC3 and Ace-1 aggressive prostate cancer cell lines.

Axiak-Bechtel SM, Kumar SR, Dank KK, Clarkson NA, Selting KA, Bryan JN, Rosol TJ, Espinosa J, Decedue CJ.

Invest New Drugs. 2013 Dec;31(6):1609-15. doi: 10.1007/s10637-013-0006-0. Epub 2013 Sep 13.

PMID:
24026433
9.

Y-chromosome DNA is present in the blood of female dogs suggesting the presence of fetal microchimerism.

Axiak-Bechtel SM, Kumar SR, Hansen SA, Bryan JN.

PLoS One. 2013 Jul 8;8(7):e68114. doi: 10.1371/journal.pone.0068114. Print 2013.

10.

Not lost in translation: how study of diseases in our pets can benefit them and us.

Henry CJ, Bryan JN.

Mo Med. 2013 May-Jun;110(3):216-9.

PMID:
23829106
11.

The future of imaging in veterinary oncology: learning from human medicine.

Mattoon JS, Bryan JN.

Vet J. 2013 Sep;197(3):541-52. doi: 10.1016/j.tvjl.2013.05.022. Epub 2013 Jun 27. Review.

PMID:
23810184
12.

A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent.

Nedrow-Byers JR, Jabbes M, Jewett C, Ganguly T, He H, Liu T, Benny P, Bryan JN, Berkman CE.

Prostate. 2012 Jun 1;72(8):904-12.

PMID:
22670265
13.

Use of samarium Sm 153 lexidronam for the treatment of dogs with primary tumors of the skull: 20 cases (1986-2006).

Vancil JM, Henry CJ, Milner RJ, McCoig AM, Lattimer JC, Villamil JA, McCaw DL, Bryan JN.

J Am Vet Med Assoc. 2012 Jun 1;240(11):1310-5. doi: 10.2460/javma.240.11.1310.

PMID:
22607597
14.

Evaluation of a B-cell leukemia-lymphoma 2-specific radiolabeled peptide nucleic acid-peptide conjugate for scintigraphic detection of neoplastic lymphocytes in dogs with B-cell lymphoma.

Statham-Ringen KA, Selting KA, Lattimer JC, Henry CJ, Green JA, Bryan JN, Jia F, Lewis MR.

Am J Vet Res. 2012 May;73(5):681-8. doi: 10.2460/ajvr.73.5.681.

PMID:
22533400
15.

Vincristine-induced central neurotoxicity in a collie homozygous for the ABCB1Δ mutation.

Krugman L, Bryan JN, Mealey KL, Chen A.

J Small Anim Pract. 2012 Mar;53(3):185-7. doi: 10.1111/j.1748-5827.2011.01155.x. Epub 2011 Nov 28.

PMID:
22122243
16.

Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu.

Mohsin H, Jia F, Bryan JN, Sivaguru G, Cutler CS, Ketring AR, Miller WH, Simón J, Frank RK, Theodore LJ, Axworthy DB, Jurisson SS, Lewis MR.

Bioconjug Chem. 2011 Dec 21;22(12):2444-52. doi: 10.1021/bc200258x. Epub 2011 Nov 14.

PMID:
22053899
17.

Identification of the most common cutaneous neoplasms in dogs and evaluation of breed and age distributions for selected neoplasms.

Villamil JA, Henry CJ, Bryan JN, Ellersieck M, Schultz L, Tyler JW, Hahn AW.

J Am Vet Med Assoc. 2011 Oct 1;239(7):960-5. doi: 10.2460/javma.239.7.960.

PMID:
21961635
18.

Monoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapy.

Bryan JN, Jia F, Mohsin H, Sivaguru G, Anderson CJ, Miller WH, Henry CJ, Lewis MR.

Cancer Biol Ther. 2011 Jun 15;11(12):1001-7. Epub 2011 Jun 15.

19.

Detection of prostate-specific membrane antigen on HUVECs in response to breast tumor-conditioned medium.

Liu T, Jabbes M, Nedrow-Byers JR, Wu LY, Bryan JN, Berkman CE.

Int J Oncol. 2011 May;38(5):1349-55. doi: 10.3892/ijo.2011.946. Epub 2011 Feb 17.

PMID:
21331445
20.

Tolerability of metronomic administration of lomustine in dogs with cancer.

Tripp CD, Fidel J, Anderson CL, Patrick M, Pratt C, Sellon R, Bryan JN.

J Vet Intern Med. 2011 Mar-Apr;25(2):278-84. doi: 10.1111/j.1939-1676.2011.0684.x. Epub 2011 Feb 11.

PMID:
21314727
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk